Next Article in Journal
FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
Next Article in Special Issue
Capturing the Biologic Onset of Inflammatory Bowel Diseases: Impact on Translational and Clinical Science
Previous Article in Journal
Nucleolar and Ribosomal Dysfunction—A Common Pathomechanism in Childhood Progerias?
Previous Article in Special Issue
A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis
Open AccessReview

Molecular Profiling of Inflammatory Bowel Disease: Is It Ready for Use in Clinical Decision-Making?

1
Laboratory of Complex Genetics, Department of Human Genetics, KU Leuven, Herestraat 49 – box 610, 3000 Leuven, Belgium
2
Department of Biochemistry and Molecular Biology, University of Ulsan College of Medicine, Seoul 05505, Korea
*
Author to whom correspondence should be addressed.
Cells 2019, 8(6), 535; https://doi.org/10.3390/cells8060535
Received: 17 April 2019 / Revised: 29 May 2019 / Accepted: 30 May 2019 / Published: 4 June 2019
Inflammatory bowel disease (IBD) is a heterogeneous disorder in terms of age at onset, clinical phenotypes, severity, disease course, and response to therapy. This underlines the need for predictive and precision medicine that can optimize diagnosis and disease management, provide more cost-effective strategies, and minimize the risk of adverse events. Ideally, we can leverage molecular profiling to predict the risk to develop IBD and disease progression. Despite substantial successes of genome-wide association studies in the identification of genetic variants affecting IBD susceptibility, molecular profiling of disease onset and progression as well as of treatment responses has lagged behind. Still, thanks to technological advances and good study designs, predicting phenotypes using genomics and transcriptomics in IBD has been rapidly evolving. In this review, we summarize the current status of prediction of disease risk, clinical course, and response to therapy based on clinical case presentations. We also discuss the potential and limitations of the currently used approaches. View Full-Text
Keywords: inflammatory bowel disease; genetics; transcriptomics; molecular profiling inflammatory bowel disease; genetics; transcriptomics; molecular profiling
Show Figures

Figure 1

MDPI and ACS Style

Lee, H.-S.; Cleynen, I. Molecular Profiling of Inflammatory Bowel Disease: Is It Ready for Use in Clinical Decision-Making? Cells 2019, 8, 535.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop